US EditionNektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
- Nektar Therapeutics will provide a live webcast of its presentation at the upcoming H.C. Wainwright BioConnect Investor Conference, scheduled for May 20, 2025, at Nasdaq Headquarters in New York City.
- On May 13, 2025, the company, headquartered in San Francisco, announced its focus on creating therapies that target immune system abnormalities involved in autoimmune and persistent inflammatory conditions.
- Nektar's lead product, rezpegaldesleukin, is a first-in-class regulatory T cell stimulator undergoing two Phase 2b trials for atopic dermatitis and alopecia areata, supported by a pipeline of immune-modulating agents.
- The webcast, featuring a fireside chat accessible through the Investor Events section on Nektar’s website, will begin at 1:30 p.m. Eastern Time and will be available for replay for 30 days.
- This event enables Nektar to communicate progress and pipeline developments to investors, reflecting its ongoing efforts to advance therapies through clinical evaluation.
Insights by Ground AI
Does this summary seem wrong?
25 Articles
25 Articles
All
Left
1
Center
13
Right
Helena Independent Record+23 Reposted by 23 other sources
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
SAN FRANCISCO, May 13, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held at the Nasdaq Headquarters in New York City…
·Helena, United States
Read Full Article
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
CARMIEL, Israel, May 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that…
Coverage Details
Total News Sources25
Leaning Left1Leaning Right0Center13Last UpdatedBias Distribution93% Center
Bias Distribution
- 93% of the sources are Center
93% Center
C 93%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
